InMed Pharmaceuticals Inc. · NASDAQ:INM
InMed Pharmaceuticals — Investor Presentation (March 2023)
22 slides from InMed Pharmaceuticals's investor presentation, March 2023
Slide 1: Corporate Presentation
Corporate Presentation March 2023 :INM www.inmedpharma.com
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements and forward-looking information within the meaning of applicable securities laws (collectively, “forward-looking statements”) including, among others, statements concerning: anticipated development activities, timelines
Slide 3: A Pure-Play Rare Cannabinoid Company
A Pure-Play Rare Cannabinoid Company RARE CANNABINOID EXPERTISE ACROSS SEVERAL AREAS Pharmaceutical Research Manufacturing Phase 2 clinical development Cannabinoid analogs Bioidentical rare cannabinoids development Multiple methods to select Skin, ocular and neurodegenerative diseases Screening of t
Slide 4: Cannabinoid Drug Development Programs
Cannabinoid Drug Development Programs
Slide 5: Pharmaceutical Development of Rare Cannabinoids
Pharmaceutical Development of Rare Cannabinoids FIRST TO ADVANCE CBN TO PHASE 2 CLINICAL TRIALS HIGHLIGHTS SCREENING PRECLINICAL PH 1 PH 2 PH 3 Phase 2 – currently enrolling INM-755 CBN Phase 1 - no systemic/adverse effects Epidermolysis bullosa Preclinical - reduced markers of inflammation & pain,
Slide 6: Epidermolysis Bullosa – A significant Unmet Medical Need
Epidermolysis Bullosa – A significant Unmet Medical Need A RARE DISEASE WITH NO APPROVED THERAPIES Unmet medical need What is EB? A rare and debilitating connective tissue disorder with no cure or approved treatments. Current treatments offer A rare genetic skin disease characterized some symptom re
Slide 7: Phase 2: INM-755 Cannabinol (CBN) Cream
Phase 2: INM-755 Cannabinol (CBN) Cream FIRST AND ONLY CBN FORMULATION TO ADVANCE TO A PHASE 2 CLINICAL TRIAL Primary Endpoint • Preliminary efficacy in treating symptoms and healing Trial expanded wounds over a 28-day period Based on safety data from Trial Design the first five adult patients, an i
Slide 8: Glaucoma – Leading Cause of Blindness for Age 60+
Glaucoma – Leading Cause of Blindness for Age 60+ CURRENT MEDICATIONS WORK TO REDUCE INTRAOCULAR PRESSURE Unmet medical need Current treatments do not proactively protect the eye or Glaucoma market reverse the progression of glaucoma and only slow the Second leading cause of blindness progression of
Slide 9: INM-088: Potential Roles for CBN in Glaucoma
INM-088: Potential Roles for CBN in Glaucoma CANNABINOL DEMONSTRATES REDUCTION OF IOP AND NEUROPROTECTIVE EFFECTS InMed data suggest CBN is the cannabinoid of choice for neuroprotection in the eye Target Effects of CBN Retina • Direct neuroprotection for the retina and optic nerve, independent of in
Slide 10: Neurodegenerative Diseases – A Gap in Treatment
Neurodegenerative Diseases – A Gap in Treatment CANNABINOIDS SHOWN TO INHIBIT NEURODEGENERATIVE DISEASE PROGRESSION IN PRECLINICAL MODELS Unmet medical need Medications to treat Alzheimer's may slow the rate of Milestones cognitive decline but none have been shown to cease or PCT patent application
Slide 11: Cannabinoids Can Act on Receptors Expressed in the Brain
Cannabinoids Can Act on Receptors Expressed in the Brain CANNABINOIDS ARE HIGHLY LIPOPHILIC Examples of receptors expressed in the brain CB1 Receptors concentrated in the brain and central nervous system but are also present in some nerves and organs GPR6 Receptors mainly expressed in the brain, par
Slide 12: Potential to enhance neuronal function
Potential to enhance neuronal function SELECTED CANNABINOID ANALOGS DEMONSTRATES NEUROPROTECTIVE EFFECTS Cannabinoid analogs increased neurite outgrowth • Selected cannabinoid analogs to advance into preclinical studies in neurodegenerative disease • Study to be conducted at the University of Britis
Slide 13: Rare Cannabinoid Manufacturing
Rare Cannabinoid Manufacturing
Slide 14: Unparalleled Cannabinoid Manufacturing Expertise
Unparalleled Cannabinoid Manufacturing Expertise ABLE TO SELECT THE MOST EFFECTIVE MANUFACTURING METHOD TO PRODUCE EACH RARE CANNABINOID Chemical Biosynthesis synthesis IntegraSyn™ • Preferred for CBs with simple • Utilizes very high efficiency, • Preferred for complex structure biosynthesis derived
Slide 15: A Reliable Solution for Rare Cannabinoid Supply
A Reliable Solution for Rare Cannabinoid Supply DELIVERING CONSISTENT, PURE, BIOIDENTICAL RARE CANNABINOIDS EVERY TIME CONSISTENCY PURITY Our reproducible processes deliver high- Our products are always THC-free, non-intoxicating quality, bioidentical rare cannabinoids with target purity levels of a
Slide 16: Producing Premium Rare Cannabinoids
Producing Premium Rare Cannabinoids LARGE SCALE BATCHES OF HIGH QUALITY, HIGHLY PURE RARE CANNABINOIDS Manufacturing Scale-Up / Launched Multiple B2B channels in R&D Development consumer health and wellness THCV June 2022 CBDV April 2022 CBT January 2022 CBC November 2019 CBL CBx Multiple rare canna
Slide 17: Corporate
Corporate
Slide 18: A Diverse Patent Portfolio
A Diverse Patent Portfolio 13 PATENT FAMILIES – NCEs/Formulations, Manufacturing Methods, Methods of Use, NCEs Manufacturing Methods of use 2 patent families filed 7 patent families filed 4 patent families filed • 21 international pending • 2 granted • 2 granted • 29 international pending • 22 inter
Slide 19: Financial Snapshot
Financial Snapshot As of 2023-03-01 Cash and Short-term Investments (as of December 31, 2022) $11.5 M Shares I/O 3.33 M Options 0.053 M Warrants and Preferred Investment Options 3.53 M Fully Diluted Shares 6.91 M Close US$1.33 52-week High US$35.50 52-week Low US$1.01 Avg. Daily Volume (Trailing 50
Slide 20: Bringing Together a Depth of Cannabinoid Expertise
Bringing Together a Depth of Cannabinoid Expertise EXTENSIVE EXPERIENCE IN PHARMA R&D, CANNABINOID/API MANUFACTURING, CLINICAL AND REGULATORY Eric A. Adams, MIBS Michael Woudenberg, PEng Alexandra Mancini, MSc Eric Hsu, PhD Sarah Li, CPA, CGA Chief Executive Officer Chief Operating Officer SVP, Clin
Slide 21: Looking forward to 2023 – Key Value Drivers
Looking forward to 2023 – Key Value Drivers • Complete Phase 2 clinical trial Q1 2023 • Advance glaucoma program towards human clinical trials • Initiate in vivo studies in neurodegenerative disease • Target proprietary cannabinoid analogs for pharma R&D • Continue to build a significant IP portfoli
Slide 22: Thank you!
UNLOCKING THE POTENTIAL OF CANNABINOID MEDICINES Thank you! Colin Clancy Vice President, Investor Relations & Corporate Communications [email protected] +1-604-416-0999 :INM www.inmedpharma.com
InMed Pharmaceuticals — Investor Presentation (March 2023) on 6ix